**List of Progress in Hematology "Review Series" 2015-2016  
\*\*\*2016\*\*\*  
Management and analyses of registry database of hematopoietic stem cell transplantation in Japan (Edited by Yoshinobu Kanda)**

1. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016; 103:3-10.
2. Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016; 103:11-9.
3. Kuwatsuka Y. Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries. Int J Hematol. 2016; 103:20-4.

**Mesenchymal Stromal/Stem Cells (Edited by Yasuo Miura)**

1. Miura Y. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology. Int J Hematol. 2016; 103:122-8.
2. Kim N, Cho S-G. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. Int J Hematol. 2016; 103:129-37.
3. Mabuchi Y, Matsuzaki Y, Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs. Int J Hematol. 2016; 103:138-44.
4. Nguyen TM, Arthur A, Gronthos S. The role of Eph/ephrin molecules in stromal–hematopoietic interactions. Int J Hematol. 2016; 103:145-54.

**Pediatric MDS/MPN (Edited by Atsushi Manabe)**

1. Hasegawa D. The current perspective of low-grade myelodysplastic syndrome in children. Int J Hematol. 2016; 103:360-4.
2. Sashida S. Evolution of myeloid leukemia in children with Down syndrome. Int J Hematol. 2016; 103:365-72.
3. Dalle J-H, de Latour RP. Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Int J Hematol. 2016; 103:373-9.
4. Kook H, Chung N-G, Kang HJ, Im HJ. Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology. Int J Hematol. 2016; 103:380-6.

**Regulation of hematopoietic stem cells (Edited by Hideo Ema)**

1. Hao S, Chen C, Cheng T. Cell cycle regulation of hematopoietic stem or progenitor cells. Int J Hematol. 2016; 103:487-97.
2. Wang Z, Ema H. Mechanisms of self-renewal in hematopoietic stem cells. Int J Hematol. 2016; 103:498-509.
3. Xiaomin W, Yajing C, Weili W, Weiping Y. mTORC signaling in hematopoiesis. Int J Hematol. 2016; 103:510-8.
4. Yu Z, Yingdai G. Novel chemical attempts at ex vivo hematopoietic stem cell expansion. Int J Hematol. 2016; 103:519-29.

**Epigenetic and metabolic regulation in hematopoiesis/leukemogenesis (Edited by Atsushi Hirao)**

1. Jiang Y, Nakada D. Cell intrinsic and extrinsic regulation of leukemia cell metabolism. Int J Hematol. 2016; 103:607-16.
2. Celik H, Kramer A, Challen GA, DNA methylation in normal and malignant hematopoiesis. Int J Hematol. 2016; 103:617-26.
3. Inoue S, Lemonnier F, Mak TW. Roles of IDH1/2 and TET2 mutations in myeloid disorders. Int J Hematol. 2016; 103:627-33.
4. Takamatsu-Ichihara E, Kitabayashi I. The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies. Int J Hematol. 2016; 103:634-42.

**Current Gene therapy for hematological disorders (Edited by Masato Yamamoto and Kenzaburo Tani)**

1. Yamamoto M, Tani K. Current status and recent advances of gene therapy in hematological diseases. Int J Hematol. 2016; 104:4-5.
2. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol. 2016; 104:6-17.
3. Osborn MJ, Belanto JJ, Tolar J, Voytas DF. Gene editing and its application for hematological diseases. Int J Hematol. 2016; 104:18-28.
4. Domingo-Musibay E, Yamamoto M. Gene and virotherapy for hematological malignancies. Int J Hematol. 2016; 104:29-41.
5. Tani K. Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world. Int J Hematol. 2016; 104:42-72.

**Recent advance in the diagnosis and treatment of bone marrow failure syndromes (Edited by Shinji Nakao)**

1. Nakao S. Diagnostic problems in acquired bone marrow failure syndromes. Int J Hematol. 2016; 104:151-2.
2. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. Int J Hematol. 2016; 104:153-8.
3. Marsh JCW, Mufti GJ. Clinical significance of acquired somatic mutations in aplastic anaemia. Int J Hematol. 2016; 104:159-67.
4. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016; 104:168-74.

**Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance (Edited by Shinsuke Iida)**

1. Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. Int J Hematol. 2016; 104:271-2.
2. Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol. 2016; 104:273-80.
3. Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016; 104:281-92.
4. Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int J Hematol. 2016; 104:293-9.
5. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016; 104:300-9.

**\*\*\*2015\*\*\***

**Molecular pathogenesis and treatment strategies ofadult leukemia (Edited by Kazunori Ohnishi)**

1. Patel B, Hirsch C, Clemente M, Sekeres M, Makishima H, Maciejewski JP. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms. Int J Hematol. 2015; 101:213-8.
2. Rodríguez D, Bretones G, Arango JR, Valdespino V, Campo E, Quesada V, López-Otín C. Molecular pathogenesis of CLL and its evolution. Int J Hematol. 2015; 101:219-28.
3. Zoi K, Cross NCP. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol. 2015; 101:229-42.
4. Yanada M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. Int J Hematol. 2015; 101:243-54.

**Transcriptional control in myeloid cell development and related diseases (Edited by Tomohiko Tamura)**

1. Imperato MR. Cauchy P, Obier N, Bonifer C. The RUNX1–PU.1 axis in the control of hematopoiesis. Int J Hematol. 2015; 101:319-29.
2. Friedman AD. C/EBPa in normal and malignant myelopoiesis. Int J Hematol. 2015; 101:330-41.
3. Tamura T, Kurotaki D, Koizumi S. Regulation of myelopoiesis by the transcription factor IRF8. Int J Hematol. 2015; 101:342-51.
4. Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int J Hematol. 2015; 101:352-61.

**The latest development in GVHD management (Edited by Makoto Murata)**

1. Shono, Y, Docampo MD, Peled JU, Perobelli SM, Jenq RR. Intestinal microbiota-related effects on graft-versus-host disease. Int J Hematol. 2015; 101:428-37.
2. Nakasone H, Sahaf B, Miklos DB. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. Int J Hematol. 2015; 101:438-51.
3. Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015; 101:452-66.
4. Murata M. Prophylactic and therapeutic treatment of graft-versus-host disease

in Japan. Int J Hematol. 2015; 101:467-86.

**Preleukemia/prelymphoma (Edited by Shigeru Chiba)**

1. Shlush LI, Zandi S, Itzkovitz S, Schuh AC. Aging, clonal hematopoiesis and preleukemia: not just bad luck? Int J Hematol. 2015; 102:513-22.
2. Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol. 2015; 102:523-7.
3. Kikushige Y, Miyamoto T. Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia. Int J Hematol. 2015; 102:528-35.